Picture courtesy ph.news.yahoo.com
Hong Kong: Two Chinese COVID-19 vaccine candidates, specifically developed to target the Omicron variant of coronavirus, have been approved for clinical trials as boosters in Hong Kong, Reuters reported.
The vaccines have been developed by units of China National Biotec Group (CNBG), according to Sinopharm subsidiary.
Both vaccine candidates contain inactivated or ‘killed’ Omicron virus and are similar to the two Sinopharm vaccines being used in China. They will be tested in adults who have already received two or three vaccine doses, CNBG said in a statement.
A study in China showed that a fourth dose of Sinopharm’s vaccine BBIBP-CorV did not significantly raise antibody levels against Omicron when administered six months after a third booster dose.
Scientists around the world are studying upgraded injections against Omicron, as vaccines based on earlier strains have not been very effective in neutralizing the highly transmissible variant.
Bhubaneswar: The Commissionerate Police detained eight workers of the Chhatra Congress for staging protest near… Read More
Mumbai: Following the tremendous success of South Indian films in recent years, Bollywood filmmakers have… Read More
Bengaluru: The Enforcement Directorate (ED) has named Karnataka Chief Minister Siddaramaiah, his family members and… Read More
Jajpur: A 14-year-old girl allegedly drugged her family members and ran away from the house… Read More
Mumbai: After delivering blockbuster hits such as ‘Bhool Bhulaiyaa’ (2007) and ‘Hera Pheri’ (2000), actor… Read More
Bhubaneswar: Kalinga Hospital Ltd (KHL) has opened a cutting-edge Emergency and Trauma Care Centre in… Read More
This website uses cookies.
